US EditionRelmada Therapeutics pivots from psilocybin to cancer, neurological disorders
Summary by Green Market Report
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
newsbudz.comReposted by 
Green Market Report
Green Market ReportRelmada Therapeutics pivots from psilocybin to cancer, neurological disorders
Relmada Therapeutics (Nasdaq: RLMD) announced Thursday it was shifting away from its previous focus on depression treatments and psychedelics, after acquiring two new Phase 2 drug candidates. The clinical-stage biotechnology company highlighted its upcoming release of topline Phase 2 data for NDV-01, which it describes as a sustained-release intravesical formulation for... Please login to read all 379 words.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
